Last reviewed 2026-04-20 · How we verify

Diflucan (Fluconazole)

Diflucan (Fluconazole) is a small molecule azole antifungal medication originally developed by Pfizer and currently owned by the same company. It targets the enzyme Cytochrome P450 3A4 to inhibit fungal growth. Diflucan is approved to treat a range of fungal infections, including candidal urinary tract infections, cryptococcal meningitis, and candidiasis of the mouth and esophagus. The medication is available as a generic product due to the expiration of its patent. Key safety considerations include monitoring liver function and potential interactions with other medications.

At a glance

Approved indications

• Candidal Urinary Tract Infection
• Candidal septicemia
• Candidal vulvovaginitis
• Candidemia
• Candidiasis of mouth
• Candidiasis of the esophagus
• Cryptococcal meningitis
• Disseminated candidiasis
• Mucocutaneous candidiasis
• Oropharyngeal Candidiasis
• Prevention of Disseminated Candidiasis

Common side effects

• Febrile neutropenia
• Drug interaction
• Candida infection
• Multiple organ dysfunction syndrome
• Sepsis
• Immune reconstitution inflammatory syndrome
• Pancytopenia
• Mucosal inflammation
• Pyrexia
• Cytokine release syndrome
• Completed suicide
• Septic shock

Drug interactions

• CYP2C19 Substrates
• High Risk QT Prolonging Agents
• dronedarone
• fluvastatin
• fosphenytoin
• imipramine
• lovastatin
• midazolam
• nortriptyline
• phenprocoumon
• phenytoin
• pimozide

Key clinical trials

• A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) (PHASE1,PHASE2)
• A Study of Olomorasib (LY3537982) in Healthy Participants (PHASE1)
• The LISA (Lactoferrin InStead of Antibiotics/Antifungals) Feasibility Study (NA)
• A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis. (PHASE3)
• A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (PHASE1,PHASE2)
• Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial (PHASE3)
• A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
• A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy Adults (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.